Skip to main content

Table 2 Treatment response

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

 

CEOP/IVE/GDP (N = 51) *

CEOP (N = 51) *

p value

Response at interim

 Complete response

17 (33.3%)

18 (35.3%)

0.834

 Partial response

26 (51.0%)

13 (25.5%)

0.008

 Stable disease

4 (7.8%)

7 (13.7%)

 

 Disease progression

3 (5.9%)

11 (21.6%)

 

 Overall response

43 (84.3%)

31 (60.8%)

0.008

Response at EOT

 Complete response

19 (37.3%)

16 (31.4%)

0.532

 Partial response

18 (35.3%)

9 (17.6%)

0.042

 Stable disease

4 (7.8%)

7 (13.7%)

 

 Disease progression

9 (17.6%)

17 (33.3%)

 

 Overall response

37 (72.5%)

25 (49. 0%)

0.015

  1. EOT end of treatment
  2. *One patient in the CEOP/IVE/GDP group could not be evaluated due to toxicity (n = 1). Two patients in the CEOP group could not be evaluated due to toxicity (n = 1) and consent withdrawal (n = 1). All the three patients were considered as no responders from statistically conservative consideration